Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Generic and Branded Low Molecular Weight Heparins Can Be Differentiated Based on Biologic and Pharmacologic Assays.

Walter P. Jeske, PhD, Paul Ackerman, B.S., Amanda Drenth, B.S., Jeanine M. Walenga, Ph.D, Mamdouh Bakhos, M.D.

Blood (2007) 110 (11): 1885.

https://doi.org/10.1182/blood.V110.11.1885.1885

Published: 2007

Journal Articles

Compositional Differences in the Oligosaccharide Components of Generic Versions of Enoxaparin and Dalteparin.

Walter P. Jeske, PhD, Aleah Brubaker, B.S., Debra Hoppensteadt, Ph.D., Jeanine M. Walenga, Ph.D., Qing Ma, Ph.D., Jawed Fareed, Ph.D.

Blood (2007) 110 (11): 3999.

https://doi.org/10.1182/blood.V110.11.3999.3999

Published: 2007

Journal Articles

Inhibition of Heparinase I by Defibrotide with Potential Clinical Implications.

Jawed Fareed, PhD, Adrian Sonevytsky, BS, Omer Iqbal, MD, Walter P. Jeske, PhD, Massimo Iacobelli, MD, Debra Hoppensteadt, PhD

Blood (2006) 108 (11): 1626.

https://doi.org/10.1182/blood.V108.11.1626.1626

Published: 2006

Journal Articles

Assay Dependent Variations in the Anticoagulant and Protamine Sulfate Neutralization Profiles of Generic Copies of Enoxaparin.

Walter P. Jeske, PhD, Jeanine M. Walenga, Ph.D., Paul D. Ackerman, B.S., Debra A. Hoppensteadt, Ph.D., Curtis Vandenberg, B.S., Rodger L. Bick, M.D., Jawed Fareed, Ph.D.

Blood (2006) 108 (11): 908.

https://doi.org/10.1182/blood.V108.11.908.908

Published: 2006

Journal Articles

The Oral, Direct Factor Xa Inhibitor BAY 59-7939 Does Not Cross-React with Anti-Heparin/PF4 (Heparin-Induced Thrombocytopenia) Antibodies.

Jeanine M. Walenga, PhD, Debra Hoppensteadt, PhD, Omer Iqbal, MD, Brian Neville, PhD, Walter P. Jeske, PhD, Margaret Prechel, PhD, Harry L. Messmore, PhD, Frank Misselwitz, MD, PhD, Mamdouh Bakhos, PhD

Blood (2005) 106 (11): 1883.

https://doi.org/10.1182/blood.V106.11.1883.1883

Published: 2005

Journal Articles

Novel Single Agents with Combined Anti-Coagulant and Anti-Platelet Activities: Potential Treatment Option for the Management of HIT.

Jeanine M. Walenga, PhD, Margaret Prechel, PhD, Walter P. Jeske, PhD, Meredith K. McDonald, BS, James M. Daikur, BS, Wasimul Haque, PhD

Blood (2005) 106 (11): 1884.

https://doi.org/10.1182/blood.V106.11.1884.1884

Published: 2005

Journal Articles

Discordance between the 1 st and 2 nd Low Molecular Weight Heparin Standards. Implications for Dosing.

Walter P. Jeske, PhD, Josephine Cunanan, MD, Debra Hoppensteadt, PhD, Jeanine M. Walenga, PhD, Omer Iqbal, MD, Michelle Florian-Kujawski, BS, Jawed Fareed, PhD

Blood (2005) 106 (11): 4158.

https://doi.org/10.1182/blood.V106.11.4158.4158

Published: 2005

Journal Articles

The Impact of Non-H:PF4 Antibodies on Results of the Serotonin Release Assay for Heparin-Induced Thrombocytopenia.

M. Margaret Prechel, PhD, Maura A. Woznica, BA, Meredith K. McDonald, BS, Walter P. Jeske, PhD, Jeanine M. Walenga, PhD

Blood (2005) 106 (11): 3952.

https://doi.org/10.1182/blood.V106.11.3952.3952

Published: 2005

Journal Articles

Von Willebrand Factor Cleaving Protease (ADAMTS-13) Antigen Levels Are Decreased in Patients with Heparin-Induced Thrombocytopenia.

Debra Hoppensteadt, PhD, Josephine Cunanan, MD, Jeanine M. Walenga, PhD, Michael P. Ero, BS, Walter P. Jeske, PhD, Rodger Bick, MD, Jawed Fareed, PhD

Blood (2005) 106 (11): 3970.

https://doi.org/10.1182/blood.V106.11.3970.3970

Published: 2005

Journal Articles

Desulfated Heparin Blocks Platelet Activation Induced by HIT Antibodies / Heparin: A New Approach to Patient Management.

Margaret Prechel, PhD, Walter P. Jeske, PhD, Meredith K. McDonald, BS, Amanda F. Drenth, BS, Jeanine M. Walenga, PhD

Blood (2004) 104 (11): 3029.

https://doi.org/10.1182/blood.V104.11.3029.3029

Published: 2004

Journal Articles

Differential Digestion of Different LMWHs by Heparinase-I and Heparinase-II: Drug Developmental Implications.

Jyothi Maddineni, BS, Walter P. Jeske, PhD, Omer Iqbal, MD, Debra A. Hoppensteadt, PhD, Jawed Fareed, PhD

Blood (2004) 104 (11): 4084.

https://doi.org/10.1182/blood.V104.11.4084.4084

Published: 2004

NARROW

Generic and Branded Low Molecular Weight Heparins Can Be Differentiated Based on Biologic and Pharmacologic Assays.

Compositional Differences in the Oligosaccharide Components of Generic Versions of Enoxaparin and Dalteparin.

Inhibition of Heparinase I by Defibrotide with Potential Clinical Implications.

Assay Dependent Variations in the Anticoagulant and Protamine Sulfate Neutralization Profiles of Generic Copies of Enoxaparin.

The Oral, Direct Factor Xa Inhibitor BAY 59-7939 Does Not Cross-React with Anti-Heparin/PF4 (Heparin-Induced Thrombocytopenia) Antibodies.

Novel Single Agents with Combined Anti-Coagulant and Anti-Platelet Activities: Potential Treatment Option for the Management of HIT.

Discordance between the 1 st and 2 nd Low Molecular Weight Heparin Standards. Implications for Dosing.

The Impact of Non-H:PF4 Antibodies on Results of the Serotonin Release Assay for Heparin-Induced Thrombocytopenia.

Von Willebrand Factor Cleaving Protease (ADAMTS-13) Antigen Levels Are Decreased in Patients with Heparin-Induced Thrombocytopenia.

Desulfated Heparin Blocks Platelet Activation Induced by HIT Antibodies / Heparin: A New Approach to Patient Management.

Differential Digestion of Different LMWHs by Heparinase-I and Heparinase-II: Drug Developmental Implications.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only